Filing Details
- Accession Number:
- 0001415889-24-005756
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-28 18:49:54
- Reporting Period:
- 2024-02-27
- Accepted Time:
- 2024-02-28 18:49:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1159036 | Halozyme Therapeutics Inc. | HALO | Biological Products, (No Disgnostic Substances) (2836) | 880488686 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1507174 | J. Michael Labarre | C/O Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130 | Svp, Chief Technical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-02-27 | 10,000 | $39.95 | 159,087 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-28 | 2,529 | $39.56 | 156,558 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-02-28 | 7,471 | $8.11 | 164,029 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-28 | 7,471 | $39.54 | 156,558 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Disposition | 2024-02-28 | 7,471 | $0.00 | 7,471 | $8.11 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 68,156 | 2026-02-03 | No | 4 | M | Direct |
Footnotes
- The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.
- Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.757 to $40.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.40 to $39.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.37 to $39.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
Billionaire Hedge Funds
